Regeneron Pharmaceuticals announced the Food and Drug Administration has approved Veopoz for the treatment of adult and pediatric patients one year of age and older with Chaple disease, also known as CD55-deficient protein-losing enteropathy. Veopoz is the first and only treatment indicated specifically for Chaple, the company said in a statement. With the approval of Veopoz, the pre-approval inspection issues related to the aflibercept 8 mg biologics license application have been addressed, it added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
- Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
- Regeneron receives EMA filing acceptance for treatment of R/R FL
- Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- Cantor biotech/biopharma analysts to hold analyst/industry conference call